Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology.
SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are also being studied as monotherapies and as part of combination treatments for certain cancers.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones. The deal also gives the German company an option to license a Hengrui antibody drug conjugate.
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover new drugs for cancer, neurology, and immunology.
Another innovation hub, in the southern city of Guangzhou, is planned for November. To date, six startups in China and other Asian countries have taken part in the German drugmaker's accelerator program.
Two drugs - Pfizer and Merck KGaA's Bavencio and AstraZeneca's Imfinzi - saw Phase III trials fail, while anticipated negative results prompted Roche to withdraw Tecentriq from regulatory review.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Merck and Palantir Technologies are forming a joint research venture called Syntropy as a way to offer data analytics tools to healthcare organizations.
As part of the collaboration. Medisafe's digital health tool will be used for Merck KGaA's drugs spanning Type 2 diabetes, thyroid disorders, and cardiovascular diseases.
Blogging will be light today on MedCity News - most of the staff is off for the Columbus Day holiday.
It’s the sort of thing that was inevitable — two companies of the same name want a Facebook page. Administrative wires got crossed and hey, presto, we have a 21st century legal dispute to resolve. In this case, Merck KGAa, based in Darmstadt, Germany, filed a request for Facebook page www.facebook.com/merck in March 2010, according […]
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.